Individuals with missense variants in the DNA binding site for TP53 tend to develop cancers with relatively high-grade malignancy, whereas carriers of missense variants in the non-DNA binding site tend to develop cancers with relatively low-grade malignancy [34, 71]. The gene discussed is TP53; the disease is cancer.